Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA)

被引：0

作者：

Glaspy, J

Berg, R

Tomita, D

Rossi, G

Vadhan-Raj, S

机构：

[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[2] Amgen Inc, Thousand Oaks, CA 91320 USA

[3] MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：760S / 760S

页数：1

共 50 条

[41] Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial
Lee Schwartzberg
Ronald Burkes
Barry Mirtsching
Timothy Rearden
Peter Silberstein
Lorrin Yee
Amy Inamoto
Tom Lillie
BMC Cancer, 10
[42] Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial
Schwartzberg, Lee
Burkes, Ronald
Mirtsching, Barry
Rearden, Timothy
Silberstein, Peter
Yee, Lorrin
Inamoto, Amy
Lillie, Tom
BMC CANCER, 2010, 10
[43] Erythroid response to epoetin alfa (EPO) 120,000 units (U) every three weeks (Q3W) initiated early or at a standard threshold in Chemotherapy Induced Anemia (CIA)
Charu, Veena
Moyo, Victor
Luo, Donghan
Wilhelm, Francois E.
BLOOD, 2007, 110 (11) : 9B - 9B
[44] Cost-effectiveness of darbepoetin alfa (DA) 500 mcg every three weeks (Q3W) with IV iron compared to DA Q3W alone in cancer patients (pts) with chemotherapy-induced anaemia (CIA)
Demarteau, N.
Annemans, L.
Mossman, T.
Bracco, A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Darbepoetin alfa given once every 3 weeks (Q3W) either synchronously or asynchronously with Q3W chemotherapy (ctx) improves anaemia in patients with breast cancer: results of a randomised, open-label study
Kim, M. Rahn
Glaspy, J.
Henry, D.
Patel, R.
Tchekmedyian, N. S.
Berg, R.
EJC SUPPLEMENTS, 2004, 2 (03): : 76 - 76
[46] A phase 3, multicentre, randomised, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) in patients on haemodialysis (HD)
Locatelli, F
Villa, G
Backs, W
Del Pino, MD
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V260 - V260
[47] A phase 2 study to evaluate the efficacy of darbepoetin-alfa administered using an extended dose schedule versus weekly dosing in cancer patients with chemotherapy-induced anemia
Rearden, T.
Schwartzberg, L.
Yee, L.
Mirtsching, B.
Charu, V.
Lam, H.
Lillie, T.
Burkes, R.
Silberstein, P.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[48] Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy.
Canon, JL
Vansteenkiste, J
Bodoky, G
Mateos, MV
Bastit, L
Ferreira, I
Rossi, G
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1098S - 1098S
[49] Treating anemia of cancer with darbepoetin alfa administered every 4 weeks: Final results from a phase 2, randomized, double-blind, placebo-controlled study in cancer patients not receiving chemotherapy and/or radiotherapy.
Gordon, David H.
Nichols, Gwen
Ben-Jacob, Ali
Lam, Hung
Lillie, Tom
Miller, Carole
BLOOD, 2006, 108 (11) : 382A - 382A
[50] Early vs standard intervention with an extended epoetin alfa (EPO) dose regimen of 120,000 units (U) every 3 weeks (Q3W) in chemotherapy (CT)-induced anemia: Results for elderly vs. younger patients in a randomized clinical trial
Charu, Veena
Moyo, Victor
Luo, Donghan
Wilhelm, Francois E.
BLOOD, 2007, 110 (11) : 8B - 9B

← 1 2 3 4 5 →